LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on VTYX stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Slutsky has given his Buy rating due to a combination of factors related to Ventyx Biosciences’ ongoing clinical developments and strategic updates. The company is advancing its Phase 2 trial for recurrent pericarditis with VTYX2735, a peripheral NLRP3 inhibitor, which has shown promising potential. The trial’s interim results, initially expected in Q4 2025, have been rescheduled to an R&D Day in Q1 2026, allowing for a more comprehensive data set and broader portfolio update.
Furthermore, the trial is expanding to include a new dosing cohort, which could expedite the readiness for Phase 3 trials. The key endpoints being evaluated, such as changes in pain scores and inflammatory markers, are critical for assessing the drug’s efficacy. The potential for VTX2735 to demonstrate superior efficacy over existing treatments like colchicine, and approach the efficacy of rilonacept, positions it as a compelling candidate in the market. These developments, along with the company’s strategic positioning, underpin Slutsky’s positive outlook and Buy rating.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 34.9% and a 49.65% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Cogent Biosciences, and Olema Pharmaceuticals.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.